Citadel Advisors
APYX icon

Citadel Advisors’s Apyx Medical APYX Stock Holding History

Citadel Advisors’s Portfolio APYX Stock Details APYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23,100
Closed -$31.6K – 12425
2025
Q1 		$31.6K Buy
+23,100
New +$31.8K ﹤0.01% 12767
2024
Q4 		– Sell
-17,800
Closed -$22.1K – 14452
2024
Q3 		$22.1K Sell
17,800
-5,200
-23% -$6.57K ﹤0.01% 12708
2024
Q2 		$30.8K Buy
23,000
+7,000
+44% +$10.3K ﹤0.01% 12239
2024
Q1 		$21.8K Buy
+16,000
New +$34K ﹤0.01% 12954
2023
Q4 		– Sell
-2,600
Closed -$8.32K – 14225
2023
Q3 		$8.32K Sell
2,600
-18,800
-88% -$87.6K ﹤0.01% 13197
2023
Q2 		$108K Buy
21,400
+14,800
+224% +$75K ﹤0.01% 10823
2023
Q1 		$19K Buy
6,600
+3,400
+106% +$9.93K ﹤0.01% 13103
2022
Q4 		$7.49K Buy
+3,200
New +$9.77K ﹤0.01% 13819
2022
Q3 		– Sell
-12,700
Closed -$74K – 12544
2022
Q2 		$74K Buy
+12,700
New +$65.2K ﹤0.01% 11656

Other funds holding APYX

RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EIM
Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SBCM
Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors's APYX Position: Q2 2026 in Review

Citadel Advisors increased its Apyx Medical (APYX) stake by 56% in Q2 2026, buying an estimated $240K and bringing the position to 168,344 shares worth $756K. The position accounts for ﹤0.01% of the portfolio, ranked #8886.

Citadel Advisors first reported a position in APYX in Q1 2016 and has held it in 25 quarters since. 68 funds tracked by Wall St. Rank hold APYX as of Q2 2026.

  • Citadel Advisors held 168,344 shares of Apyx Medical worth $756K as of Q2 2026.
  • Citadel Advisors bought 60,546 Apyx Medical shares in Q2 2026, an estimated $240K.
  • Apyx Medical made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8886 holding.
  • Citadel Advisors first reported a position in Apyx Medical in Q1 2016 and has held it in 25 quarters since.
  • 68 funds tracked by Wall St. Rank held Apyx Medical as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.